"H" for Heterogeneity in the Algorithm for Type 2 Diabetes Management

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacogenomics

Background:

• Type 2 diabetes (T2D) exhibits considerable genetic, socioeconomic, and clinical heterogeneity.
• This variability influences disease progression and response to pharmacologic therapies.
• Current T2D treatment often lacks personalization, leading to suboptimal outcomes and high treatment failure rates.

Purpose of the Study:

• To review the multifaceted nature of T2D heterogeneity.
• To assess current strategies for addressing T2D variability in clinical practice.
• To identify knowledge gaps in developing personalized therapeutic approaches for T2D.

Main Methods:

• Literature review of studies on T2D heterogeneity.
• Analysis of existing research on patient stratification and biomarker discovery.
• Examination of clinical trial data related to T2D treatment response.

Main Results:

• Pathophysiology-based clustering shows promise for stratifying T2D patients.
• Novel biomarkers are needed to identify distinct metabolic pathways and inform therapeutic decisions.
• Significant gaps remain in translating personalized approaches into routine T2D care.

Conclusions:

• Addressing T2D heterogeneity is crucial for improving treatment efficacy and reducing long-term complications.
• Personalized therapeutic strategies require a deeper understanding of individual patient features.
• Future research should focus on biomarker development and clinical studies for tailored T2D management.